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Abstract
Background:  Biochemical marker combinations, including α2-macroglobulin, haptoglobin,
apolipoprotein A1, γ-glutamyl transpeptidase, and total bilirubin (all part of FibroTest) plus alanine
aminotransferase (all part of ActiTest), are being developed as alternatives to liver biopsy in
patients with chronic hepatitis C and other various chronic liver diseases. Considering this premise,
the primary aim of this study was to assess the impact of meal intake on FibroTest and ActiTest
results. Such studies are very important for patients, as many clinical errors have been related to
the absence of baseline evidence.
Results: Intra-individual variation was assessed for the 6 above components and for FibroTest and
ActiTest, by measuring time dependent variations before and one hour after a standard meal in 64
subjects. These consisted of 29 healthy volunteers and 35 patients with chronic liver diseases. Meal
intake had no significant impact on any of the six components, or on FibroTest or ActiTest, as
assessed by repeated measure variance analyses (ANOVA all p > 0.90); the Spearman correlation
coefficient ranged from 0.87 (total bilirubin) to 0.995 (γ-glutamyl transpeptidase). The coefficients
of variation (CV) between fasting and postprandial measurements fluctuated for the six
components from 0.09 (apolipoprotein A1) to 0.14 (α2-macroglobulin), and from 0.09 for
FibroTest to 0.13 for ActiTest. In contrast, meal intake had a significant impact on triglycerides
(ANOVA p = 0.01, CV = 0.65) and glucose (ANOVA p = 0.04, CV = 0.31). As for the prediction
of liver injury, the concordance between fasting and postprandial predicted histological stages and
grades was almost perfect, both for FibroTest (kappa = 0.91, p < 0.001) and ActiTest (kappa = 0.80,
p < 0.001).
Conclusions: The intra-individual variation of biochemical markers was low, and it was shown that
measurements of FibroTest, ActiTest and their components are not significantly modified by meal
intake. This fact makes the screening of patients at risk of chronic liver diseases more convenient.
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Background
One of the major clinical problems facing the medical
community is how to best evaluate and manage the
increasing numbers of patients with chronic liver diseases,
including patients infected with hepatitis C virus (HCV)
[1]. According to the latest consensus conferences, liver
biopsy is still recommended in most patients [2,3]. How-
ever, recent studies strongly suggest that due to the limita-
tions [4-6] and risks of biopsy [7], as well as the
improvement of the diagnostic accuracy of biochemical
markers [8,9], liver biopsy should no longer be consid-
ered mandatory.
Liver biopsy has three major limitations: the risk of
adverse events [7], sampling error [4-6], and inter- and
intra- pathologist variability [10,11]. An overview of pub-
lished studies summarizes the risks of liver biopsy as pain
(around 30%), severe adverse events (3/1000) and death
(3/10 000) [7]. Sampling variation is the major cause of
variability [4-6]. Bedossa et al. [6] observed very high coef-
ficients of variation (55%) and high discordance rates
(35%) for fibrosis staging in biopsies measuring 15 mm
in length. The variability significantly improved in biop-
sies with 25 mm in length, but it was still very high, with
a 45% coefficient of variation and 25% discordance rate
[6].
Among the non-invasive alternatives to liver biopsy [9],
numerous studies have demonstrated the predictive value
of two combinations of simple serum biochemical mark-
ers in patients infected with HCV and HBV: FibroTest (FT)
(Biopredictive, Houilles, France) for the assessment of
fibrosis, and ActiTest (AT) (Biopredictive, Houilles,
France) for the assessment of necroinflammatory activity
[8,12-22]. Similar results have not been obtained by other
diagnostic tests [9,12-14,16-22].
One concern regarding of biochemical panels is the varia-
bility due to the different components [23,24]. For FT, AT,
and their six components, the inter- and intra laboratory
variability has been shown to be acceptable without sig-
nificant consequence on predictive values when pre-ana-
lytical and analytical recommendations were applied
[25,26].
Because of the large number of patients who could benefit
from these markers, it would be practical if fasting were
not required for the determinations. Thus far, very few
studies have looked at the impact of meal intake on liver
tests, and none have been done specifically on the fibrosis
markers [27-34].
The aim of this study was to assess the impact of meal
intake on FibroTest and ActiTest results by measuring time
dependent variations before and one hour after a standard
meal in 64 subjects. A secondary goal was to gain a better
understanding of the relationship of liver function tests
with fasting and meals.
Results
A total of 65 subjects were screened between November
21st  and December 19th  2003. These consisted of 35
patients and 30 apparently healthy volunteers. One vol-
unteer did not come for the postprandial measurements
and was therefore excluded. The characteristics of the 64
included subjects are given in Table 1. The only significant
difference between healthy volunteers and patients char-
acteristics, not directly related to liver disease, was the
younger age of the former.
The analysis of inter- and intra-individual variability
according to meal intake is given in Table 2 and data are
quoted for all 64 subjects. Meal intake had no significant
impact on any of the six biochemical components, nor on
FibroTest or ActiTest, as assessed by repeated measure var-
iance analysis; the Spearman correlation coefficient
ranged from 0.87 (total bilirubin) to 0.995 (γ-glutamyl
transpeptidase). The coefficients of variation between fast-
ing and postprandial measurements fluctuated, for the six
components, from 0.09 (apolipoprotein A1) to 0.14 (α2-
macroglobulin), and 0.09 for FibroTest and 0.13 for
ActiTest. In contrast, meal intake had a significant impact
on triglycerides and glucose.
As for the prediction of liver injury, the concordance
between fasting and postprandial predicted histological
fibrosis stages and activity grades was almost perfect for
both FibroTest and ActiTest (Tables 3,4).
When each individual variation was analyzed, very few
variations were observed. No FT varied more than 0.10
points. No factors were found to be associated in
multivariate analysis (Table 5). Only one AT result varied
more than 0.10 decimals, from 0.34 to 0.52. This was in
an apparently healthy volunteer with a small increase of
fasting ALT (75 IU/l) and an increase in postprandial ALT
(115 IU/l). Fasting and postprandial FT's were normal.
The total calories of the meal were 790 kcal, of which 41%
were lipids and 42% carbohydrates. A complete medical
analysis was performed (viral markers, auto-immune
markers, ultrasonography, thyroid hormones) which
found no cause of chronic liver disease. The only abnor-
mal findings were a small increase in body mass index
(26.8 kg/m2), long-term medication use of the contracep-
tive pill and the ingestion of a NSAID (ibuprofen) for pel-
vic pain 48 hours before sampling.
There was no significant association between patients'
characteristics and the dietary components of the meal
(Table 5). One patient did not fill out the dietary ques-Comparative Hepatology 2004, 3 http://www.comparative-hepatology.com/content/3/1/3
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Table 1: Characteristics of included apparently healthy volunteers and patients
Apparently healthy volunteers Patients
Number of patients 29 35
Characteristics
Age (years) [mean (SD)]*** 36 (8) 52 (15)
Male [n (%)] 12 (41) 22 (63)
Female [n (%)] 17 (59) 13 (37)
Ethnic Origin
Caucasian [n (%)] 19 (65) 20 (60)
Non Caucasian [n (%)] 10 (35) 15 (40)
Black/Asian/Other (n) 5/1/4 5/3/7
Weight (kg) [mean (SD)] 68.2 (10.8) 69.7 (14.8)
Height [mean (SD)] 170 (9.5) 169 (7.6)
Body Mass Index (kg/m2) [mean (SD)] 23.6 (3.4) 24.4 (5.1)
Alcohol in g per day [n (%)]
0 21 (72) 21 (64)
0–50 8 (28) 8 (24)
Over 50 0 (0) 4 (12)
Drug [n (%)] 8 (28) 29 (83)
Anti-diabetic (n) 0 7
Oral contraception (n) 2 7
Other (n) 6 15
Associated Disease 03 5
Alcoholic Liver Disease (%) 0 10 (29)
Hepatitis C (%) 0 6 (17)
Hepatitis B (%) 0 4 (11)
Human Immunodeficiency Virus Infection (%) 0 1 (3)
Other (%) 0 14 (40)
Histological prediction fasting
Necrotico-inflammatory activity
No or minimal activity (%) 28 14
Moderate or severe activity (%) 1 21
Fibrosis
No or minimal fibrosis (%) 28 14
Moderate (%) 1 5
Extensive fibrosis or cirrhosis (%) 0 16
Baseline Biochemistry fasting
ALT (IU/L) [mean (SD)]*** 23.7 (16.3) 67.4 (53.8)
Total Bilirubin (µmoles/L) [mean (SD)] 13.9 (7.6) 27.1 (31.7)
GGT U/L (7–32 female) (11–49 male) [mean (SD)]*** 21 (15.9) 147 (149)
Alpha2 macroglobulin g/L (1.6–4.0) [mean (SD)] 1.77 (0.43) 2.15 (0.78)
ApoA1 g/L (1.2–1.7) [mean (SD)]* 1.56 (0.24) 1.26 (0.55)
Haptoglobin g/l (0.35–2.00) [mean (SD)] 1.06 (0.35) 0.86 (0.66)
Conjugated bilirubin (µmoles/L) [mean (SD)]* 3.25 (1.5) 28.9 (22.5)
Gilbert possible (%) 7 0
Fibrosis Index (range 0.00–1.00) [mean (SD)]*** 0.13 (0.08) 0.55 (0.33)
Activity Index (range 0.00–1.00) [mean (SD)]*** 0.09 (0.1) 0.42 (0.24)
AST (IU/L) [mean (SD)]*** 26 (10) 60 (34)
Triglycerides (umol/L) [mean (SD)] 1.0 (0.76) 1.7 (2.6)
Cholesterol (umol/L) [mean (SD)] 4.8 (1.2) 4.5 (1.8)
Blood glucose (umol/L) [mean (SD)]** 4.2 (0.56) 5.9 (3.12)
Dietary factors
Total calories (kcal) 788 774
Lipids (%) 38 35
Carbohydrates (%) 45 44
Proteins (%) 15 18
Fibers (g) 6 8
*Significant difference between groups P < 0.05; **Significant difference between groups P < 0.001; ***Significant difference between groups P < 
0.0001.Comparative Hepatology 2004, 3 http://www.comparative-hepatology.com/content/3/1/3
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Table 2: Inter and intra-individual variability of FibroTest and ActiTest components and two positive controls (glucose and triglycerides) 
according to fasting
A2M     
g/L
HPT      
g/L
APOA
1 g/L
BT 
µmol/L
GGT     
U/L
ALT    
U/L
Fibro 
Test
Acti  
Test
Glucose Triglycerides
Mean (SD)
Fasting 1.98 
(0.67)
0.95 
(0.55)
1.40 
(0.46)
21 (25) 90 (127) 48 (47) 0.36 
(0.33)
0.27 
(0.25)
5.09 
(2.43)
1.38 (1.97)
Postprandial 1.99 
(0.64)
0.96 
(0.53)
1.40 
(0.46)
21 (24) 88 (123) 47 (42) 0.36 
(0.33)
0.27 
(0.25)
6.17 
(3.15)
1.88 (1.94)
Spearman Coefficient 0.96 0.98 0.94 0.87 0.995 0.98 0.98 0.98 0.45 0.75
ANOVA p value 0.92 0.93 0.98 0.99 0.98 0.94 0.98 0.94 0.04 0.01
Coefficient of 
Variation (log)*
Inter-individual Fasting 0.34 
(0.50)
0.58 (-
2.85)
0.33 1.17 
(0.28)
1.41 
(0.30)
0.98 
(0.23)
0.91 0.27 0.48 1.43
Inter-individual 
Postprandial
0.32 
(0.48)
0.55 (-
2.93)
0.33 1.15 
(0.29)
1.40 
(0.30)
0.90 
(0.22)
0.90 0.27 0.51 1.03
Intra-individual 
Regression **
0.10 
(0.14)
0.13 (-
0.41)
0.09 0.25 
(0.10)
0.14 
(0.02)
0.18 
(0.04)
0.09 0.13 0.31 0.65
Data are quoted for all 64 subjects. * As all components except apolipoprotein A1 are computed using the logarithmic transformation in FibroTest 
and ActiTest formulas, the coefficient of variation was also assessed in log for these five components. ** Represents the intra-individual variability of 
the linear regression between fasting and postprandial values.
Table 3: Fibrosis stages – Concordance between fibrosis stages and predictions using fasting or postprandial assessments
Fasting
Postprandial No or minimal Fibrosis Moderate Fibrosis Severe Fibrosis
No or minimal Fibrosis 39 0 0
Moderate Fibrosis 3 6 0
Severe Fibrosis 0 0 16
Kappa statistic = 0.91 (SD = 0.76); p < 0.001; almost perfect concordance.
Table 4: Activity stages – Concordance between Activity grades predictions using fasting or postprandial assessments
Fasting
Postprandial No or minimal Activity Moderate Activity Severe Activity
No or minimal Activity 51 1 0
Moderate Activity 2 3 1
Severe Activity 0 0 6
Kappa statistic = 0.80 (SD = 0.77); p < 0.001; almost perfect concordance.Comparative Hepatology 2004, 3 http://www.comparative-hepatology.com/content/3/1/3
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tionnaire and he was consequently non-included in the
dietary analysis.
Discussion
This study demonstrated that a standard meal does not
induce significant changes in the components' measure-
ments, nor in the FT and AT values and predictions of his-
tological lesions. This finding could facilitate the
screening of liver injury in different chronic liver diseases,
such as chronic hepatitis C [12-19] and B [20], alcoholic
liver [35] or non-alcoholic steatosis [36], by replacing
liver biopsy with biochemical markers. FT and AT cannot
replace liver biopsy of sufficient quality (40 mm length)
in clinical research or as a second line diagnostic tool for
difficult cases in clinical practice. However, these markers
should replace liver biopsy for routine estimation of liver
injury in chronic liver diseases. The variability of the com-
ponents and of FT-AT has been already studied for the pre-
analytical and analytical steps [26], as well as for the inter-
laboratory variability [25].
The analytical imprecision of the component results had
only a slight impact on the FibroTest and ActiTest values.
Intra-laboratory variability of fibrosis and activity indices
was minor, ensuring the validation of clinically relevant
diagnostic thresholds for significant fibrosis and activity.
It was concluded that FibroTest and ActiTest component
measurements must be performed on fresh serum or that
which had been stored at -80°C. We also observed that
the intra- and interseries imprecision of each parameter
assay and of FT-AT were acceptable in the utilized analyt-
ical system, with the CV at about 5%. The upper CV of the
ActiTest results (9.9%) in interseries imprecision was
related to the lack of accuracy of the low normal ALT activ-
ity measurement itself. The logarithmic expression of
results in the algorithm used for FibroTest and ActiTest
calculations minimizes the influence of analytical
imprecision, in particular for GGT, ALT and total
bilirubin. Variability in the same patient of 2 FT and AT
results at an interval of 4 days was also acceptable in spite
of isolated wider variations in components results [26].
The influence of gender was observed for all parameters
except haptoglobin. ALT activity, as previously described,
GGT activity, α2-macroglobulin, and haptoglobin levels
were influenced by body mass index [26].
Curiously, very few studies have been published on the
fasting or non-fasting variability of the 6 FT-AT compo-
nents. Concentrations of 27 commonly estimated serum
constituents were measured in blood sampled from 20
apparently healthy volunteers at 08:30, 12:30, and 16:30
hours on four consecutives days (at weekly intervals).
Time-dependent statistically significant variations were
observed for bilirubin, triglycerides, total protein, and
albumin. An interesting finding for α2 macroglobulin and
haptoglobin, two main non-albumin proteins included in
FT-AT, was that the variation of total protein was related
to albumin variation, with higher concentrations in the
morning than in the afternoon [27]. Patterns of bilirubin
variation were variable, but there was a tendency for it to
decrease in the afternoon samples. No statistically signifi-
cant diurnal or weekly variation was observed for ALT, α2-
macroglobulin, immunoglobulins (IgA, IgM, IgG), or
cholesterol [27].
In the present study, the intra-individual variability was
very low for total bilirubin, and for GGT and ALT serum
activities (when expressed as logarithmic values). The
mean variability observed was even lower than that
observed previously between 2 measurements at 4 day
intervals [26]. In only one case was there a difference in
ALT, which was 43 IU/l more in the postprandial period,
being a 60% increase in activity. This induced a difference
in the ActiTest of 0.18.
Table 5: Association between postprandial variations of FibroTest-ActiTest and dietary factors
FibroTest ActiTest
Spearman Coefficient (significance p)
Characteristics
Age +0.03 (0.80) -0.11 (0.37)
Body Mass Index -0.04 (0.73) -0.03 (0.83)
Meal components
Total Calories -0.11 (0.38) -0.02 (0.87)
Lipids -0.11 (0.38) -0.12 (0.35)
Carbohydrates -0.24 (0.06) -0.02 (0.87)
Fiber +0.02 (0.90) -0.14 (0.26)Comparative Hepatology 2004, 3 http://www.comparative-hepatology.com/content/3/1/3
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We observed a non-significant intra-individual variability
related to meals for α2-macroglobulin. Morrison et al. had
already observed this [27], and Narita et al. also found
that fractional clearance of α2-macroglobulin was not
affected by protein meals as compared to smaller plasma
inflammation proteins, such as ceruloplasmin or γ-globu-
lins in healthy subjects [37].
No particular study has looked at postprandial variations
of haptoglobin. As haptoglobin is associated with inter-
leukin-6 and tumor-necrosis factor, it is possible that a
modification of these cytokines could change the serum
concentration. It is reassuring that a short-term isoener-
getic, very low carbohydrate diet did not affect markers of
inflammation, including interleukin-6, despite a signifi-
cant decrease of fasting and postprandial triglycerides and
an increase of HDL-cholesterol [31]. Keeping in line with
these results, Morrison et al. also observed that non-albu-
min proteins (which include haptoglobin) were not mod-
ified after meals [27].
Apolipoprotein A1 variations have been studied in
patients with hyperlipemia and cardiovascular diseases
[30-34]. Mutation of the apolipoprotein A1 gene affects
the LDL-cholesterol response to diet via mechanisms
involving postprandial lipoprotein cholesterol metabo-
lism [34]. There was a significant postprandial decrease in
plasma cholesterol, LDL cholesterol, and apolipoprotein
B in G/G subjects but not in G/A subjects. No significant
genotype effects were detected for apolipoprotein A1 and
HDL-cholesterol concentrations. [30,34] In the present
study the variability related to meal intake was also much
greater for triglycerides (Table 2) than for apolipoprotein
A1.
Lipoprotein profiles change markedly during cardiac cath-
eterisation [38], with total cholesterol triglycerides and
apolipoprotein A1 serum concentrations decreasing sig-
nificantly from the baseline concentrations. These
changes were probably related to the activation of lipo-
protein lipase due to heparin injection [39].
In the present study, the dietary characteristics of the meal
were not associated with significant post-prandial varia-
tions. However, as the median total calories of the meal
was 782 kilo-calories with a maximum of 1340 kcal, it is
prudent to recommend a meal of around 800 kcal.
Conclusions
This study shows that the biochemical markers of liver
fibrosis (FibroTest) and activity (ActiTest) is low, and that
these two tests can be performed in postprandial periods
in order to facilitate the management of patients with
chronic liver diseases.
Methods
Subjects
Two groups of subjects were included. The first was a
group of apparently healthy volunteers without known
liver disease. The second were patients hospitalized in our
Department of Hepato-Gastroenterology due to chronic
liver disease. Subjects with a history of gastric surgery were
excluded, as were subjects unwilling to eat their usual
lunch meal and subjects who refused to sign the informed
consent.
Questionnaire
A questionnaire with 17 items was filled out which
included clinical characteristics and the details of the
lunch in term of calories, fat, protein and carbohydrate
composition according to Prodiet software (Nutrilog, Ver-
sailles, France) (Table 1).
Design of the study
After giving consent for the study, subjects had one blood
sample drawn between 7 and 10 a.m. after 10 hours of
night fasting, and on the same day a postprandial blood
sample was drawn 1 hour after the end of the usual meal.
Blood samples were obtained from patients by venous
puncture and collected in 5 ml glass tubes without antico-
agulant. Serum samples were separated after coagulation,
by centrifugation. The centrifugation conditions con-
formed to the recommendations of the Vacutainer tube
manufacturers (Becton Dickinson Franklin Lakes NJ,
USA). 500 µl was sufficient for the 6 parameters assays.
Biochemical markers
We used the previously validated FT-AT [8,12-22]. FT
combines the following five markers, all independently
related to fibrosis, as well as age and gender: α2-mac-
roglobulin, haptoglobin, γ-glutamyl transpeptidase (GGT
EC: 2.3.2.2), total bilirubin, and apolipoprotein A1. AT
combines the same five markers plus alanine amino trans-
ferase (ALT EC: 2.6. 1. 2). The results of FT-AT can range
from 0.00 to 1.00, with a conversion to METAVIR stages
and grades calculated from median scores and 95% confi-
dence intervals, which had been previously observed in
1,270 patients and 300 healthy blood donors
[8,12,26,40]. GGT, ALT and total bilirubin were measured
by a Hitachi Modular DP automat from Roche Diagnos-
tics (Mannheim, Germany), using the manufacturer rea-
gents. ALT was assessed according to the standard method
recommended by the IFCC (International Federation of
Clinical Chemistry), using pyridoxal phosphate as the
activator [41]. GGT activity was assessed according to the
Szasz method, standardized against the original method
published by Persijn and Van der Slik [42], and total
bilirubin by a diazoreaction according to the Wahlefeld
method [43]. The assays for these three parameters were
calibrated with a CFAS (calibrator for automated systemsComparative Hepatology 2004, 3 http://www.comparative-hepatology.com/content/3/1/3
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from Roche Diagnostics). ALT enzymatic activity of the
calibrator was determined with the reference method
using the molar absorption coefficient (ε) measurement
of NADPH, measured at 339 nm. The calibrator GGT
activity was determined with the Szasz reference method
using the coefficient ε measurement of amino-5 nitro-2
benzoate at 410 nm. The calibrator bilirubin concentra-
tion was determined using the Standard Reference Mate-
rial (SRM) 909b, and assessed according to the Doumas
reference method [44].
The  α2-macroglobulin, apolipoprotein A1, and hap-
toglobin were measured using a Modular analyzer (BNII,
Dade Behring; Marburg, Germany). All CV assays were
lower than 6%. Reagents used for the assays were stand-
ardized against the International Certified Reference
Material 470 (CRM 470) for α2-macroglobulin and hap-
toglobin, and against the reference material of the World
Health Organization – International Federation of Clini-
cal Chemistry SP1-01 (WHO- IFCC SPI-01) for apolipo-
protein A1 [45,46]. Glucose, triglycerides and cholesterol
were measured by Hitachi Modular.
Statistical methods
Intra-individual variability according to fasting and post-
prandial measurements was assessed by repeated variance
analysis, the Spearman rank coefficient of correlation and
the coefficient of variation (standard variation divided by
the mean). The coefficient of variation was calculated for
the fasting, the postprandial values and the intra-individ-
ual regression analysis. Calculations were made with reg-
ular values and used logarithmic transformation for the 5
components expressed as a log value in the FibroTest and
ActiTest algorithm. The coefficient of variation for the lin-
ear regression was computed by dividing the square root
of the mean square error of the linear correlation coeffi-
cient (between fasting and postprandial values) by the
mean of the fasting value [47].
Two serum biochemical parameters, glucose and triglycer-
ides, which are well known to increase after meals, were
used as positive controls.
The possible impact of age, body mass index, total meal
calories, and respective calories due to carbohydrates and
lipids on postprandial variation was assessed by the
Spearman coefficient of correlation.
Analysis by kappa statistics was performed to assess the
degree of concordance between predicted fibrosis stages
(three classes using the METAVIR scoring system: no or
portal fibrosis; few septa; many septa or cirrhosis) and
grades (three classes using the METAVIR scoring system:
no or minimal necrosis; moderate necrosis; severe necro-
sis) [10,11]. The strength of agreement was considered
slight for values between 0 and 0.19, fair for values
between 0.20 and 0.39, moderate for values between 0.40
and 0.59, substantial for values between 0.60 and 0.79,
and almost perfect if kappa values were greater than 0.80
[48,49]. All statistical analyses were performed with
Number Cruncher Statistical Systems 2001 (NCSS, Kay-
sville, UT) software [47]. Data were expressed as mean
(SD). Comparisons between patients and healthy volun-
teers were done with the non-parametric Mann-Whitney
U test.
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